Showing 4711-4720 of 5646 results for "".
- Innovations Will Propel OCT Market to $549 Million in Revenue in 2020https://modernod.com/news/innovations-will-propel-oct-market-to-549-million-in-revenue-in-202/2478426/Recent innovations in optical coherence tomography (OCT) technology—such as systems that are combined with fundus imagers—and software advancements, including OCT angiography, are growing in popularity. At the same time promising new technologies on the horizon, such as at-home OCT devices, are g
- New World Medical Registers New KDB GLIDE for Smooth, Precise Goniotomyhttps://modernod.com/news/new-world-medical-registers-new-kdb-glide-for-smooth-precise-goniotomy/2478414/New World Medical announced FDA registration of the KDB GLIDE as a Class 1 device, designed to give surgeons a refined, precise experience performing excisional goniotomy for treatment of glaucoma. The KDB GLIDE device improves on the successful Kahook Dual Blade technology by adding new features
- J&J Pauses COVID-19 Vaccine Studies After “Unexplained Illness”https://modernod.com/news/jj-pauses-covid-19-vaccine-studies-after-unexplained-illness/2478407/Johnson & Johnson confirmed that it paused further dosing in all clinical studies of its COVID-19 vaccine candidate JNJ-78436735, including the phase 3 ENSEMBLE trial, due to an “unexplained illness” in a participant. The company noted that the subject’s illness is being rev
- Bausch Health Licenses Eyenovia’s Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12https://modernod.com/news/bausch-health-licenses-eyenovias-investigational-treatment-for-the-reduction-of-pediatric-myopia-progression-in-children-ages-3-12/2478405/Bausch Health Companies and Eyenovia announced that an affiliate of Bausch Health has acquired an exclusive license in the United States and Canada for the development and commercialization of an investigational microdose formulati
- EyeCare4Kids Partners with 1-800 Contacts to Launch Sight the Worldhttps://modernod.com/news/eyecare4kids-partners-with-1-800-contacts-to-launch-sight-the-world/2478400/1-800 Contacts and nonprofit EyeCare4Kids announced the launch of Sight the World, which will utilize innovative vision care technology from 1-800 Contacts to provide free glasses and contact lenses for underserved adults and children globally. The announcement comes on World Sight Day, an intern
- Lilly, Incyte’s Olumiant Shows “Significant Effect” on COVID-19 Recovery Timeshttps://modernod.com/news/lilly-incytes-olumiant-shows-significant-effect-on-covid-19-recovery-times/2478401/Eli Lilly and Incyte shared more details, including mortality data, from the ongoing ACTT 2 trial evaluating their JAK1/JAK2 inhibitor Olumiant (baricitinib) in combination with Gilead Sciences’ Veklury (remdesivir) in patients with COVID-19 infection. The companies said last month that the
- CooperVision Presents 6-Year Data from MiSight 1 Day Studyhttps://modernod.com/news/coopervision-presents-6-year-data-from-misight-1-day-study/2478397/CooperVision is reporting the latest findings from its landmark MiSight 1 day clinical study, providing new insights about myopia management and the efficacy of the specially designed contact lens. Among many powerful outcomes are that nearly one in four children’s eyes originally fit with MiSigh
- AIVITA Biomedical’s Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Sciencehttps://modernod.com/news/aivita-biomedicals-stem-cell-therapeutic-in-vision-loss-published-in-investigative-ophthalmology-vision-science/2478398/AIVITA Biomedical announced the publication of the peer-reviewed manuscript, “Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction,” in the journal Investigative Ophthalmology & Visual Science. The
- Regeneron Asks FDA to Approve Emergency Use of REGN-COV2 for COVID-19https://modernod.com/news/regeneron-asks-fda-to-approve-emergency-use-of-regn-cov2-for-covid-19/2478394/Regeneron Pharmaceuticals said that it submitted a request to the FDA seeking emergency-use authorization for its REGN-COV2 investigational antibody combination for the treatment of COVID-19. REGN-COV2 is a combination of two monoclonal antibodies, REGN10933 and REGN10987, which has been designed
- Alcon Celebrates World Sight Day 2020 and Continues Commitment to Improving Worldwide Access to Eye Carehttps://modernod.com/news/alcon-celebrates-world-sight-day-2020-and-continues-commitment-to-improving-worldwide-access-to-eye-care/2478392/Alcon celebrates World Sight Day through its corporate giving and company-led initiatives focused on improving access to quality eye care. In the spirit of this year’s theme, “Hope in Sight,” Alcon associates will help spark donations to global nonprofit organizations that advance eye health. The